001047477 001__ 1047477
001047477 005__ 20251031202036.0
001047477 0247_ $$2doi$$a10.1111/adb.12745
001047477 0247_ $$2ISSN$$a1355-6215
001047477 0247_ $$2ISSN$$a1369-1600
001047477 037__ $$aFZJ-2025-04328
001047477 082__ $$a540
001047477 1001_ $$0P:(DE-HGF)0$$aRohleder, Cathrin$$b0
001047477 245__ $$aDifferent pharmaceutical preparations of Δ9‐tetrahydrocannabinol differentially affect its behavioral effects in rats
001047477 260__ $$aHoboken, NJ [u.a.]$$bWiley-Blackwell$$c2020
001047477 3367_ $$2DRIVER$$aarticle
001047477 3367_ $$2DataCite$$aOutput Types/Journal article
001047477 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1761901873_15049
001047477 3367_ $$2BibTeX$$aARTICLE
001047477 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001047477 3367_ $$00$$2EndNote$$aJournal Article
001047477 520__ $$aBased on the contribution of the endocannabinoid system to the pathophysiology of schizophrenia, the primary pro-psychotic ingredient of Cannabis sativa, Δ-9-tetrahydrocannabinol (Δ-9-THC), is used in preclinical as well as clinical research to mimic schizophrenia-like symptoms. While it is common to administer lipid-based formulations of Δ-9-THC in human studies orally, intraperitoneal injections of water-based solutions are used in animal models. Because of the poor water solubility of Δ-9-THC, solubilizers such as ethanol and/or emulsifiers are needed for these preparations. In order to test whether a lipid-based solvent would be superior over a water-based vehicle in rats, we compared the effects on locomotor activity and prepulse inhibition (PPI) of the acoustic startle reaction, as well as pharmacokinetic data obtained from rats' serum and brain tissue samples. Up to 50 mg/kg Δ-9-THC in the lipid-based formulation was not able to induce any behavioral alterations, while already 5 mg/kg of the water-based Δ-9-THC preparation significantly reduced locomotor activity. This also induced a small but significant PPI reduction, which was prepulse intensity dependent. Interestingly, the reflexive motor response to the startle stimulus was not affected by the water-based Δ-9-THC solution. Analysis of serum and brain Δ-9-THC levels by high-performance liquid chromatography/mass spectrometry revealed that although the final concentration reached in the brain was comparable for both pharmaceutical preparations, the water-based formulation achieved a faster kinetic. We, therefore, conclude that the slope of the Δ-9-THC concentration-time curve and the resulting cannabinoid receptor type 1 activation per time unit are responsible for the induction of behavioral alterations.
001047477 536__ $$0G:(DE-HGF)POF4-5253$$a5253 - Neuroimaging (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001047477 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001047477 7001_ $$0P:(DE-HGF)0$$aPahlisch, Franziska$$b1
001047477 7001_ $$0P:(DE-HGF)0$$aGraf, Rudolf$$b2
001047477 7001_ $$0P:(DE-Juel1)180330$$aEndepols, Heike$$b3$$ufzj
001047477 7001_ $$00000-0002-8163-195X$$aLeweke, F. Markus$$b4$$eCorresponding author
001047477 773__ $$0PERI:(DE-600)1495537-4$$a10.1111/adb.12745$$gVol. 25, no. 3, p. e12745$$n3$$pe12745$$tAddiction biology$$v25$$x1355-6215$$y2020
001047477 8564_ $$uhttps://juser.fz-juelich.de/record/1047477/files/Addiction%20Biology%20-%202019%20-%20Rohleder%20-%20Different%20pharmaceutical%20preparations%20of%209%E2%80%90tetrahydrocannabinol%20differentially.pdf$$yRestricted
001047477 909CO $$ooai:juser.fz-juelich.de:1047477$$pVDB
001047477 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)180330$$aForschungszentrum Jülich$$b3$$kFZJ
001047477 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001047477 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-18$$wger
001047477 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-18$$wger
001047477 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bADDICT BIOL : 2022$$d2024-12-18
001047477 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-18
001047477 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-18
001047477 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-18
001047477 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-18
001047477 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-18
001047477 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-18
001047477 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-18
001047477 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-18
001047477 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-18
001047477 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-18
001047477 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-18
001047477 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-18
001047477 920__ $$lyes
001047477 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x0
001047477 980__ $$ajournal
001047477 980__ $$aVDB
001047477 980__ $$aI:(DE-Juel1)INM-5-20090406
001047477 980__ $$aUNRESTRICTED